Fatigue will be at its worst 2 to 3 weeks after prophylactic cranial irradiation (PCI)
ID
Bron
Verkorte titel
Aandoening
fatigue, small cell lung cancer (SCLC), PCI
vermoeidheid, kleincellig longcarcinoom, profylactische schedelbestraling
Ondersteuning
Onderzoeksproduct en/of interventie
Uitkomstmaten
Primaire uitkomstmaten
Onset and level of fatigue after PCI measured by VAS
Achtergrond van het onderzoek
Cancer related fatigue (CRF) is a common problem in oncological patients. 50-90% of oncological patients experience fatigue, the highest percentage is found in patients treated with chemo- and/or radiotherapy. CRF is one of the most important complaints related to cancer and its treatment. It is also a strong and independent predictor of quality of life (QoL) and patient satisfaction. After PCI, SCLC patients experience significantly more fatigue than patients who have not had PCI. Duration of fatigue after PCI is approximately 3 months, but no data exist regarding onset and peak of fatigue complaints after PCI. To plan starting time and duration of fatigue-modifying treatment, we want to evaluate in this study onset, peak and duration of fatigue after PCI (only in SCLC stage I-III) by VAS and other questionnaires
Doel van het onderzoek
Fatigue will be at its worst 2 to 3 weeks after prophylactic cranial irradiation (PCI)
Onderzoeksopzet
first questionnaires to be completed in week before PCI, the first month after PCI the questionnaires have to be completed every week, the next two months the questionnaires have to be completed every two weeks
Onderzoeksproduct en/of interventie
questionnaires:
regarding fatigue: VAS and MVI-20
regarding quality of life: EORTCc30 and EuroQol 5D
Publiek
PO Box 5800
L. Hendriks
Maastricht 6202 AZ
The Netherlands
+31 (0) 43 387 6543
lizza.hendriks@mumc.nl
Wetenschappelijk
PO Box 5800
L. Hendriks
Maastricht 6202 AZ
The Netherlands
+31 (0) 43 387 6543
lizza.hendriks@mumc.nl
Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)
-Age >=18 years
-SCLC, pathology proven
-Completed initial treatment, with at least stable disease
-WHO PS ¡Ü 2
-Ability to understand written questionnaires
-Written informed consent
Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)
- clinically relevant anemia (defined as Hb < 6 mmol/l)
- chronic renal failure (defined as MDRD-eGFR < 45 ml/min/1.73m)
- liver biochemistry abnormalities (defined as more than two times upper limit of normal)
- major psychiatric illness requiring intervention in secondary care
Opzet
Deelname
Opgevolgd door onderstaande (mogelijk meer actuele) registratie
Geen registraties gevonden.
Andere (mogelijk minder actuele) registraties in dit register
Geen registraties gevonden.
In overige registers
| Register | ID |
|---|---|
| NTR-new | NL4067 |
| NTR-old | NTR4218 |
| Ander register | : METC 13-4-074 |
| ISRCTN | ISRCTN wordt niet meer aangevraagd |